Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)

Numerous placebo-controlled studies have demonstrated the ability of ketamine, an NMDA receptor antagonist, to induce rapid (within hours), transient antidepressant effects when administered intravenously (IV) at subanesthetic doses (0.5 mg/kg over 40 min). However, the optimal antidepressant dose r...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Molecular psychiatry Ročník 25; číslo 7; s. 1592 - 1603
Hlavní autoři:	Fava, Maurizio, Freeman, Marlene P, Flynn, Martina, Judge, Heidi, Hoeppner, Bettina B, Cusin, Cristina, Ionescu, Dawn F, Mathew, Sanjay J, Chang, Lee C, Iosifescu, Dan V, Murrough, James, Debattista, Charles, Schatzberg, Alan F, Trivedi, Madhukar H, Jha, Manish K, Sanacora, Gerard, Wilkinson, Samuel T, Papakostas, George I
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	England Nature Publishing Group 01.07.2020
Témata:	Adult Antidepressants Antidepressive Agents - therapeutic use Blood pressure Depression - drug therapy Depressive Disorder, Treatment-Resistant - drug therapy Double-Blind Method Double-blind studies Female Glutamic acid receptors (ionotropic) Humans Infusions, Intravenous Intravenous administration Ketamine Ketamine - administration & dosage Ketamine - therapeutic use Male Mental depression Midazolam Middle Aged N-Methyl-D-aspartic acid receptors Placebos Treatment Outcome Treatment resistance
ISSN:	1359-4184, 1476-5578, 1476-5578
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!